SEC Comment Letter 0000000000-23-006179 to Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)

Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: June 8, 2023 · CIK: 0001601936 · Accession: 0000000000-23-006179

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-272336

Date

June 8, 2023

Author

Division of Corporation Finance

Form

UPLOAD

Company

Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)

Letter

United States securities and exchange commission logo June 8, 2023 Dr. Thomas Meyer President Altamira Therapeutics Ltd. 8 The Green, Suite 12455 Dover, DE 19901

Re: Altamira Therapeutics Ltd. Registration Statement on Form F-1 Filed June 1, 2023 File No. 333-272336

Dear Dr. Thomas Meyer:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Cindy Polynice at 202-551-8707 with any questions.

Sincerely,
Division of Corporation Finance

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo

                          June 8, 2023

       Dr. Thomas Meyer
       President
       Altamira Therapeutics Ltd.
       8 The Green, Suite 12455
       Dover, DE 19901

                                                        Re: Altamira
Therapeutics Ltd.
                                                            Registration
Statement on Form F-1
                                                            Filed June 1, 2023
                                                            File No. 333-272336

       Dear Dr. Thomas Meyer:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Cindy
Polynice at 202-551-8707 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Steven Skolnick, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io